Introduction
Approximately 30% of patients with epilepsy have refractory epilepsy, i.e. seizures persist despite accurate diagnosis and carefully monitored treatment with antiepileptic (AEDs) drugs. 1, 2 The ketogenic diet (KD) is a high-fat, adequate-protein and very low-carbohydrate diet that has been used for many years to treat intractable epilepsy in children. The KD has been shown to be effective in retrospective, prospective and randomized controlled studies. [3] [4] [5] [6] In a randomized controlled trial, after 3 months of the KD, 38% of patients had >50% seizure reduction compared with 6% of the controls, while 7% of patients had >90% seizure reduction compared with none of the controls. 5 In Korean and American multicentric studies, more than 40-50% of patients had a >50% reduction in seizure frequency after 6 and 12 months. 6, 7 More recently, the modified Atkins diet has been used to treat intractable epilepsy. [8] [9] [10] [11] [12] [13] The modified Atkins diet induces ketosis without fluid, calorie or protein restriction, nor the requirement for fasting or food weighting. Daily carbohydrates are limited and high-fat intake encouraged. The modified Atkins diet was designed to be a less restrictive alternative than the KD. Early studies have suggested efficacy and safety in both children and adults. [8] [9] [10] [11] [12] [13] The mechanisms by which the KD and modified Atkins diet exert their anti-seizure effects are not clear. Among the possible mechanisms of action, it has been hypothesized that various fatty acids, by influencing neuronal excitability, may constitute part of beneficial effects of KD on seizure control. [14] [15] [16] [17] [18] [19] [20] [21] In a study of 9 children on KD, elevated blood polyunsaturated fatty acid (PUFA) was found. The rise in arachidonic acid (AA) was correlated with seizure control. 22 However, a decrease in serum AA and an increase of linoleic (LA) and eicosapentaenoic (EPA) acids were found in another study including 25 patients. 23 In the latter, no correlation between serum fatty acids levels and seizure control was found. We report our experience using both classic KD and modified Atkins diet in children with refractory epilepsy. Our aim was to compare the relative efficacy of the diets and to evaluate serum long chain fatty acids profiles.
The ketogenic diet (KD) and the modified Atkins diet are effective therapies for intractable epilepsy. We compared retrospectively the KD and modified Atkins diet in 27 children and also assessed serum long chain fatty acid profiles. After 3 months, using an intent-to-treat analysis, the KD was more successful, with >50% seizure reduction in 11/17 (65%) vs. 2/10 (20%) with the modified Atkins diet, p = 0.03. After 6 months, however, the difference was no longer significant: 7/17 (41%) vs. 2/10 (20%) (p = 0.24). We observed a preventive effect of both diets on the occurrence of status epilepticus. After 1 and 3 months of either diet, responders experienced a significant decrease in serum arachidonic acid concentration compared to non-responders. The KD and modified Atkins diet led to seizure reduction in this small pilot series, with slightly better results after 3 months with the KD, but not after 6 months. The decrease of serum arachidonic acid levels might be involved in the anticonvulsive effects of KD or modified Atkins diet.
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consisted of 27 patients with intractable childhood epilepsy who had been experiencing more than 2 seizures per week which could not be controlled by at least three anticonvulsant drugs. All seizure types were permitted. No child with prior exposure to either the KD or the modified Atkins diet was included.
Study design
The seizure frequency was determined from parental and medical notes (seizure calendar) at baseline (1 month) and during the follow-up (1, 3, 6 and 12 months on the diet). Children with a 50% seizure reduction were classified as non-responders and those with a >50% seizure reduction as responders.
The occurrence of convulsive status epilepticus was compared before and after the start of the diets. We included in this analysis the patients that remain at least 3 months on diet.
At our institution, a non-fasting KD protocol was used from September 2002 to January 2007 but was later replaced by the modified Atkins diet. The classic KD was introduced without initial fasting and fluid restriction. The total caloric amount was given in three days (day 1: 1/3; day 2: 2/3; day 3: 3/3). All patients received the KD with a lipid-to-nonlipid ratio of either 4:1 or 3:1.
The modified Atkins diet consisted of 60% fat, 30% protein, and 10% carbohydrates by weight, without the restriction of recommended daily calories according to patient age. The modified Atkins diet was also introduced without initial fasting. As suggested by Kossoff et al., 12 for the first month carbohydrates were restricted to 10 g/day, but were permitted to increase by 5 g/ day at intervals of at least 1 month when the child was having difficulty with the restriction of carbohydrates, to a maximum of 10% carbohydrates per day by weight. Following the start of either diet, all patients were advised to remain in the hospital for 3-4 days to ensure adequate diet adaptation. A qualified dietician (EB) also educated the caregivers/ parents about preparation of the diet at home. Follow-up clinic visits at 1, 3, 6 and 12 months after initiating either diet were obtained to assess efficacy, tolerability, and associated serum long chain fatty acid profile.
Fatty acids profiling
Early morning blood samples were obtained from children prior to the initiation of the diet and were planned after 1, 3, 6 and 12 months on either diet. After addition of internal standard (C19:0; 20.2 mg/ml), serum lipids were extracted with chloroform/ methanol (2/1, v/v) using a method adapted from this described by Folch et al. 24 Lipids were hydrolyzed and methylated with sulphuric acid and methanol. Fatty acid methyl esters obtained were separated by gas-liquid chromatography using a 30-m Supelco Omé gawax TM 320 fused-silica capillary column. Analysis was performed on a Varian 3400 gas chromatograph (Varian, Palo Alto, CA) equipped with flame ionization detector. Helium was used as carrier gas and column conditions were optimized to separate all the peaks of interest: C14:0, C16:0, C16:1, C18:0, C18:1, C18:2 n-6, C18:3: n-3, C20:3 n-6, C20:5 n-3, C20:3 n-9, C20:4 n-6, C22:6 n-3. Results are expressed as percentage of total fatty acids (mean AE S.E.M.).
Statistical analyses
Statistical Package for the Social Science (version 15.0) (SPSS Chicago, IL) was used for all statistical analyses and a p-value <0.05 was regarded as statistically significant. Categorical data were analyzed using Fisher exact test. Means (AES.E.M.) were analyzed using Mann-Whitney test. (Table 1 ). For 2 patients (patients 7 and 8), KD was replaced by the modified Atkins diet after 5 and 11 months, respectively. The median age at seizure onset was 6 months (range: birth-66 months). The epilepsy syndromes of the included patients were: 30% infantile spasms (8/ 27), 56% partial epilepsy (15/27), 11% generalized epilepsy (3/27) and 3% Lennox-Gastaut syndrome (1/27) . A median of 7 AEDs (range: 3-14) had been attempted before diet initiation. The median age at KD onset was 32 months (range: 11-153 months) and at modified Atkins diet onset was 77 months (range: 4-182 months). Children were receiving a median of 3 AEDs at diet initiation (range: 2-4) ( Table 2 ).
Results

Patient demographics
Treatment efficacy and duration
All children completed at least 1 month on diet. To date, 1 patient remains on the KD and 5 patients are still on the modified Atkins diet. The median diet duration was 5 months (range: for the KD and 3 months (range: 1-6) for the modified Atkins diet. Twenty-nine percent remained on the KD after 12 months compared to 20% on the modified Atkins diet.
After 1 month, 10 of 17 (59%) children receiving the KD were >50% improved, compared to 5/10 (50%) of those receiving the modified Atkins diet (p = 0.28). Using an intent-to-treat analysis, after 3 months, 11 of 17 (64%) on the KD were improved, compared to 2 of 10 (20%) with modified Atkins (p = 0.03). After 6 months, the difference was no longer significant: 7/17 (41%) vs. 2/10 (20%) (p = 0.24). Ten of 17 children have stopped the KD (seizure free (n = 3), ineffective (n = 7), intolerance (n = 1)) whereas 5/10 stopped modified Atkins diet (ineffective (n = 4), intolerance (n = 2)). After 12 months, 8 patients were still on diet (6 KD; 2 modified Atkins diet). The comparison was not possible due to the small number of patients. None of our patient has had major side effects. We observed mild digestive disorders in 2 patients on KD and in 1 patient on the modified Atkins diet (Fig. 1) .
There was no difference in the number of anticonvulsants before and after diet treatment. The occurrence of convulsive status epilepticus significantly decreased after the diet initiation (analysis done for 24 patients that remain at least 3 months on diet). Before either diet, the median occurrences of status epilepticus was 1 (range: 0-12) while the median was 0 (range: 0-2) while receiving dietary therapy (p = 0.005). 
Levels of serum fatty acids
Patients 4, 7, 12, 15, and 17 had serum total lipid long chain fatty acids profile before and 1, 3, 6 and 12 months after treatment initiation, respectively. Significant changes in several fatty acids were found (Fig. 2) . As for the omega-6 (n-6) and omega-3 (n-3) fatty acids: linoleic (LA; C18:2 n-6) and alpha-linolenic (ALA; C18:3 n-3) acids were increased at 1, 3, 6 and 12 months, whereas homolinoleic acid (C20:3 n-6), arachidonic acid (AA; C20:4 n-6), eicosapentaenoic acid (EPA; C20:5 n-3), docosahexaenoic acid (DHA, C22:6 n-3) and eicosatrienoic acid (mead; C20:3 n-9) were unchanged after 1, 3, 6 or 12 months on either diet. For the monounsaturated fatty acids, consistent changes were seen in palmitoleic acid (C16:1), which was significantly reduced after 1, 6 and 12 months under treatment. Saturated fatty acids levels were unchanged after 1, 3, 6 or 12 months under treatment.
Levels of serum fatty acid and efficacy at 1 and 3 months
The levels of each fatty acid at 1 and 3 months of diet were statistically compared according to responder (>50% seizure reduction) and non-responder ( 50% seizure reduction) status (Fig. 3) . After 1 month, children who were responders (n = 7) had a significant increase of serum palmitoleic acid and a significant decrease of AA compared to non-responder (n = 8). AA values were 5.57 AE 0.73% and 9.06 AE 0.81% in responder and non-responder patients, respectively. There was a slight decrease in serum EPA in responders (p = 0.06). After 3 months, responders (n = 6) had lower serum AA and DHA compared to non-responders (n = 6). AA values were 6.17 AE 0.63% and 8.99 AE 1.10% and DHA values were 1.77 AE 0.22% and 2.46 AE 0.15% in responder and non-responders, respectively. LA and ALA serum levels were not different between groups after 1 and 3 months.
Discussion
The KD and the modified Atkins diet seem to exert overall comparable efficacy for children with intractable epilepsy over a 6-month period. Our overall results are similar to what has been published in the United States and Asia for the modified Atkins diet in children, although slightly fewer efficacies was seen in our series beyond the 1-month point than elsewhere. [8] [9] [10] [11] [12] [13] This is the first report of the use of modified Atkins diet in children in Europe to our knowledge. Regarding the serum total lipid long chain fatty acid measurements, an increase of serum LA, ALA, and palmitoleic acid was observed for the patients on these diets. Children who responded to these diets experienced a significant decrease of AA concentration after 1 and 3 months while a significant decrease of DHA concentration was observed in responders after 3 months. It is highly unlikely that AED are involved in PUFA modification as only one patient received oxcarbazepine at that time (Table 1) .
We agree with reports at other institutions by parents or caregivers that the modified Atkins diet is well-tolerated by children. 9, 12 In this study, diet duration was generally equal between these groups, with 20-29% of children remaining on either diet after 12 months. Two children were able to transition from the KD to modified Atkins without subsequent decrease in efficacy.
Our results also demonstrated that KD and the modified Atkins diet may have a preventative effect on the occurrence of status epilepticus (SE). In addition to the anticonvulsant effect of the diets, the possible prevention of morbidity and mortality from SE may be an important additional benefit. Few clinical data are available on the use of KD or the modified Atkins diet in children with SE, with only our single case report of the use of KD in an adult. 25 Both in vivo [14] [15] [16] [17] 20, 26 and in vitro 18, 19, 21 experimental studies have demonstrated anticonvulsant effects of PUFA. However, the anticonvulsant properties of PUFA in clinical trials are conflicting. [27] [28] [29] A previous study including 9 patients receiving the KD reported a significant increase of AA and DHA after 1 month. The increase in total serum AA was correlated with improvement seizure control. 22 Another study of 25 children receiving the KD reported a decrease of AA. 23 No correlation between serum fatty acids and seizure frequency was found. 23 In our study, responder patients showed a significant decrease of serum AA after 1 and 3 months. We also found a significant decrease of DHA concentrations in responder patients after 3 months. Among the experimental studies showing anticonvulsant effects of PUFA, we recently showed the absence of links with the brain phospholipids modification. However, the rats treated by KD or by an ALA/LA mixture experienced a decrease of serum AA concentrations.
14 Another recent study showed a dose dependant anticonvulsant effect of LA and ALA (SR-3 mixture) associated to a raise in n-3 PUFA unesterified fatty acids in the brain in pentylenetetrazole (PTZ) induced seizure in rats. 17 While a study using mice showed a decrease of serum AA concentration after EPA or DHA (n-3 PUFA) treatment, there was no change in PTZ, fluorothyl or 6 Hz seizure thresholds. 30 In vitro studies have shown that extracellular application of PUFA produces a concentrationdependent shift of the voltage dependence of inactivation of both Na + and Ca 2+ currents to more hyperpolarized potentials. The use of n-6 PUFA (LA) were less effective on both Na + and Ca 2+ currents inhibition than n-3 PUFA. 18 Others studies reported that AA (n-6) increased cellular excitability by inhibiting depolarization-activated K + currents and transient K + currents in both CA1 pyramidal neurons and inhibitory interneurons. 31, 32 Further study is needed to evaluate if KD and/or modified Atkins diet efficacy may be related to a serum AA decrease that could lead to decrease neuronal excitability.
In conclusion, both the KD and modified Atkins diet appear to demonstrate similar efficacy in children with intractable epilepsy over a 6-month period. The modified Atkins diet was welltolerated as well. As a result of our findings, it is now our primary dietary therapy for children. Furthermore, it seems that seizures do not appear to increase when the modified Atkins diet is substituted for the KD, as has been noted previously in one child. 10 Further study is needed to assess this issue, including switching patients who do not respond to the modified Atkins diet to the classical KD. Finally, we observed that responder patients treated by KD or modified Atkins diet had decreased serum AA levels. The decrease of AA should be further explored in order to understand its role in the anticonvulsant effect of dietary therapies. ; LA + ALA: linoleic acid (C18:2 n-6) + alpha-linolenic acid (C18:3 n-3); homo lino: homo linoleic acid (C20:3 n-6); EPA: eicosapentaenoic acid (C20:5 n-3); mead: eicosatrienoic (C20:3 n-9); AA: arachidonic acid (C20:4 n-6); DHA: docosahexaenoic acid (C22:6 n-3). oleic acid (C18:1); LA + ALA: linoleic acid (C18:2 n-6) + alpha-linolenic acid (C18:3 n-3); homo lino: homo linoleic acid (C20:3 n-6); EPA: eicosapentaenoic acid (C20:5 n-3); mead: eicosatrienoic (C20:3 n-9); AA: arachidonic acid (C20:4 n-6); DHA: docosahexaenoic acid (C22:6 n-3).
